Phase 1 Trial to Assess Safety and Immunogenicity of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)
Randomized, Double-Blinded, Placebo-Controlled Phase 1 Clinical Trial to Assess the Safety and Immunogenicity of Two Doses of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) in Healthy Participants
Herpes zoster is caused by reactivation of varicella zoster virus. This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of self-replicating RNA (srRNA) herpes zoster vaccine JCXH-105. Eligible participants will receive 2 doses of study vaccine/placebo at planned dose levels and follow scheduled safety and immunogenicity follow-up visits. The goal of this study is to assess the safety profile and immune response induced by JCXH-105.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 1
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
(1) Gender: Male or female; (2) Age: ≥ 40 years of age at screening. (3) Status: Healthy participants. (4) Subject agrees not to receive any other herpes zoster vaccine while participating in this study.
(5) All Laboratory values required for screening prior to study enrollment are within normal limits or abnormal without clinical significance as judged by the investigator.
(6) Female participants must meet the following criteria:
-
Surgically sterile or postmenopausal for ≥ 2 years, or women of childbearing potential (premenopausal or postmenopausal for < 2 years) who have a negative pregnancy test and are willing to use effective contraception from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.
-
Agree not to breastfeed from the first administration of investigational vaccine/placebo to at least 3 months after the full-course vaccination.
(7) Male participants should meet the following criteria: agree to use effective contraception and not to donate sperms from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.
(8) Able to fully understand and voluntarily sign the informed consent form.
-
Exclusion Criteria:
-
(1) Participants who have a history of herpes zoster or are currently diagnosed with herpes zoster, or have a history of chickenpox, or a history of close contact with chickenpox/herpes zoster patients within 30 days before enrollment.
(2) History of chickenpox or herpes zoster vaccination. (3) Hypersensitivity to any component of the investigational vaccine/placebo, or any previous serious reaction to vaccination, or a history of serious allergic disease.
(4) Fever within 3 days prior to enrollment, acute illness or acute exacerbation of chronic illness within 7 days prior to enrollment, or taking antipyretic, analgesic, and anti-allergic drugs within 3 days prior to enrollment.
(5) History of significant cardiac disease, or myocarditis or pericarditis. (6) At present, participants with severe liver and kidney diseases, spleen dysfunction or asplenia, hypertension that cannot be controlled by drugs, diabetes with serious complications and other chronic diseases are currently suffering.
(7) Use of whole blood, blood products, or immunoglobulins within 3 months prior to vaccination or planned use during the study.
(8) Has received any inactive vaccine within 14 days prior to the first dose of vaccine.
(9) Received the following within 28 days prior to the first dose of vaccine: Any live/mRNA vaccine; Immunomodulators or immunosuppressive drugs; Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor; Receiving systemic corticosteroids for 3 or more consecutive days. (Note: Study participants are permitted to receive long-term systemic prednisone at a dose ≤10 mg/day, or systemic corticosteroids equivalent to prednisone. Topical medications such as ointments, eye drops, inhalants or nasal sprays are allowed, provided that the topical medications should not exceed the recommended dose in the instructions and there are no signs of systemic exposure.) (10) Have confirmed or suspected immunosuppression, immunodeficiency, or autoimmune disease.
(11) Positive screening test for HIV antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies.
(12) Known history of active or latent tuberculosis (Mycobacterium tuberculosis).
(13) Axillary temperature > 37.0 °C at enrollment. (14) Participation in another drug, device, or other vaccine clinical trial within 30 days prior to the first dose of investigational vaccine/placebo or planned participation during the study period.
(15) Participants with dermatologic condition that could affect local solicited adverse reaction assessments (e.g., tattoos, psoriasis, patches affecting skin over the deltoid area).
(16) Participants with contraindications to IM injection. (17) The investigator considers that there are other situations unsuitable for participating in this study, including but not limited to failure to participate in follow-up according to the study protocol.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Low-dose JCXH-105
Participants receive low dose of JCXH-105 |
Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) |
|
Comparador de Placebo: Low-dose placebo
Participants receive low dose of placebo |
Placebo (sodium chloride injection) as control |
|
Experimental: Medium-dose JCXH-105
Participants receive medium dose of JCXH-105 |
Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) |
|
Comparador de Placebo: Medium-dose placebo
Participants receive medium dose of placebo |
Placebo (sodium chloride injection) as control |
|
Experimental: High-dose JCXH-105
Participants receive high dose of JCXH-105 |
Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) |
|
Comparador de Placebo: High-dose placebo
Participants receive high dose of placebo |
Placebo (sodium chloride injection) as control |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Serious adverse events (SAEs)
Prazo: From Day 1 post- administration through 360 days after the full-course vaccination
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
From Day 1 post- administration through 360 days after the full-course vaccination
|
|
Solicited local injection site adverse events
Prazo: Within 14 days after each dose of investigational vaccine/placebo
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
Within 14 days after each dose of investigational vaccine/placebo
|
|
Solicited systemic adverse events
Prazo: Within 14 days after each dose of the investigational vaccine/placebo
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
Within 14 days after each dose of the investigational vaccine/placebo
|
|
Unsolicited AEs
Prazo: Within 30 days after each dose of the investigational vaccine/placebo
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
Within 30 days after each dose of the investigational vaccine/placebo
|
|
Laboratory parameters
Prazo: On the third day after each dose of the investigational vaccine/placebo
|
Clinically significant abnormal changes of laboratory parameters compared with pre-vaccination |
On the third day after each dose of the investigational vaccine/placebo
|
|
Adverse events of special interest (AESIs)
Prazo: From Day 1 post administration through 360 days after the full-course vaccination
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
From Day 1 post administration through 360 days after the full-course vaccination
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- JCXH-105-002
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .